Brachytherapy Boost Techniques for Locally Advanced Prostate Cancer

ONCOLOGY

Volumn 13, Issue 4, 1999, Pages

  Vicini, Frank A ^a   Kestin, Larry L ^b   Stromberg, Jannifer S ^b   Martinez, Alvaro A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRACHYTHERAPY; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; HUMAN; MALE; METHODOLOGY; PROGNOSIS; PROSTATE TUMOR; RADIATION DOSE; RECTUM; REVIEW;

BRACHYTHERAPY; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RECTUM; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 0033113757     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Amling CL, Blute ML, Bergstralh EJ, et al: Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer. Semin Urol Oncol 15(4):222-229, 1997.
2. Amling CL, Leibovich BC, Lerner SE, et al: Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. Semin Urol Oncol 15(4):215-221, 1997.
3. Connolly JA, Shinohara K, Carroll PR: Cryosurgery for locally advanced (T3) prostate cancer. Semin Urol Oncol 15(4):244-249, 1997.
4. Corn BW, Valicenti RK, Mulholland G, et al: Stage T3 prostate cancer: A non-randomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy. Urology 51:782-787, 1998.
5. Epstein JI, Pound CR, Partin AW, et al: Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol 160:97-101, 1998.
6. Eulau SM, Corn BW: Combinations of hormones and local therapies in locally advanced prostate carcinoma. Oncology 10(8):1193-1202, 1996.
7. Forman JD, Porter AT: The experience with neutron irradiation in locally advanced adenocarcinoma of the prostate. Semin Urol Oncol 15(4):239-243, 1997.
8. Fowler JE, Bigler SA, Kolski JM, et al: Early results of a prospective study of hormone therapy for patients with locally advanced prostate carcinoma. Cancer 82:1112-1117, 1998.
9. Gerber GS, Thisted RA, Chodak GW, et al: Results of radical prostatectomy in men with locally advanced prostate cancer: Multi-institutional pooled analysis. Eur Urol 32:385-390, 1997.
10. Mordkin RM, Hayes WS, Kuettel MR, et al: Management of locally advanced prostate cancer. Oncology 10(9):1289-1300, 1996.
11. Moul JW: Contemporary hormonal management of advanced prostate cancer. Oncology 12(4):499-505, 1998.
12. Roach M, Meehan S, Kroll S, et al: Radiotherapy for high-grade clinically localized adenocarcinoma of the prostate. J Urol 156:1719-1723, 1996.
13. Zietman AL, Westgeest JCM, Shipley WU: Radiation-based approaches to the management of T3 prostate cancer. Semin Urol Oncol 15(4):230-238, 1997.
14. Hanks GE, Diamond JJ, Krall JM, et al: A 10-year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States. Int J Radiat Oncol Biol Phys 13:499-505, 1987.
15. Forman JD, Oppenheim T, Liu H: The frequency of residual neoplasm in the prostate following three-dimensional conformal radiotherapy. Prostate 23:235-243, 1993.
16. Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol 15:1013-1021, 1997.
17. Egawa S, Wheeler TM, Greene DR, et al: Detection of residual prostate cancer after radiotherapy by sonographically guided needle biopsy. Urology 39:358-363, 1992.
18. Partin AW, Kattan MW, Subong ENP, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 277:1445-1451, 1997.
19. Partin AW, Yoo J, Carter HB, et al: Use of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:110-114, 1993.
20. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997.
21. Laverdiere J, Gomez JL, Cusan L, et al: Beneficial effect of combination hormonal therapy administered prior and following external beam irradiation in localized prostate cancer. Int J Radiat Oncol Biol Phys 37:247-252, 1997.
22. Pilepich MV, Krall JM, Al-Sarraf M, et al: Androgen deprivation with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:616-623, 1995.
23. Pilepich MV, Buzydlowski JW, John MJ, et al: Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: Outcome results of RTOG 83-07. Int J Radiat Oncol Biol Phys 32:175-180, 1995.
24. Modig H, Tomic R, Grantors, et al: Prospective randomized trial in localized prostatic cancer: Radiotherapy vs radiotherapy and orchidectomy (abstract 1323). Proc ESTRO, 1993.
25. Zagars GK, Johnson DE, von Eschenbach AC, et al: Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: Long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 14:1085-1091, 1988.
26. Fuks Z, Leibel SA, Wallner KE, et al: The effects of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with iodine-125 implantation. Int J Radiat Oncol Biol Phys 21:537-544, 1991.
27. Fuks Z, Whitmore WF, Leibel S, et al: Local control is associated with decreased distant failure in early stage carcinoma of the prostate. Int J Radiat Oncol Biol Phys 17(suppl 1):121, 1989.
28. Zelefsky MJ, Whitmore WF: Long-term results of retropubic permanent iodine-125 implantation of the prostate for clinically localized prostatic cancer. J Urol 158:23-30, 1997.
29. Fukunaga-Johnson N, Sandler HM, McLaughlin PW, et al: Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 38:311-317, 1997.
30. Hanks GE, Hanlon AL, Schultheiss TE, et al: Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41:501-510, 1998.
31. Hanks GE, Lee WR, Hanlon AL, et al: Conformai technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > 10 ng/ml. Int J Radiat Oncol Biol Phys 35:861-868, 1996.
32. Hanks GE, Schultheiss TE, Hanlon AL, et al: Optimization of conformai radiation treatment of prostate cancer: Report of a dose escalation study. Int J Radiat Oncol Biol Phys 37:543-510, 1997.
33. Pollack A, Zagars GK: External beam radiotherapy for stage T1/T2 prostate cancer: How does it stack up? Urology 51:258-264, 1998.
34. Zelefsky MJ, Leibel SA, Gaudin PB, et al: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41:491-500, 1998.
35. Forman JD, Duclos M, Sharma R, et al: Conformal mixed neutron and photon irradiation in localized and locally advanced prostate cancer: Preliminary estimates of the therapeutic ratio. Int J Radiat Oncol Biol Phys 35:259-266, 1996.
36. Haraf DJ, Rubin SJ, Sweeney P, et al: Photon neutron mixed-beam radiotherapy of locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 33:3-14, 1995.
37. Forman JD, Orton C, Ezzell G, et al: Preliminary results of a hyperfractionated dose escalation study for locally advanced adenocarcinoma of the prostate. Radiother Oncol 27:203-238, 1993.
38. Shipley WU, Verhey LJ, Munzenrider JE, et al: Advanced prostate cancer: The results of a randomized comparative trial of high-dose irradiation boosting with conformai protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32:3-12, 1995.
39. Yonemoto LT, Slater JD, Rossi CJ, et al: Combined proton and photon conformal radiation therapy for locally advanced carcinoma of the prostate: Preliminary results of a phase I/II study. Int J Radiat Oncol Biol Phys 37:21-29, 1997.
40. Critz FA, Levinson AK, Williams WH, et al: Prostate-specific antigen nadir: The optimum level after irradiation for prostate cancer. J Clin Oncol 14:2893-2900, 1996.
41. Stock RG, Stone NN, Tabert A, et al: A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41:101-108, 1998.
42. Epstein JI, Pound CR, Partin AW, et al: Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol 160:97-101, 1998.
43. Green GA, Hanlon AL Al-Saleem T, et al: A Gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy. Cancer 83:971-976, 1998.
44. Anderson PR, Hanlon AL, Patchefsky A, et al: Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA < 10 ng/ml treated with conformal external beam radiation therapy. Int J Radiat Oncol Biol Phys 41:1087-1092, 1998.
45. 3 identifies patients with localized prostatic cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy. J Clin Oncol 16:3094-3100, 1998.
46. Ragde H, Elgamal AA, Snow PB, et al: Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gy external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 83:989-1001, 1998.
47. Whitmore WF Jr, Hilaris B, Grabstald H: Retropubic implantation of iodine 125 in the treatment of prostate cancer. J Urol 108:918-920, 1972.
48. Critz FA, Levinson K, Williams WH, et al: Prostate-specific antigen nadir of 0.5 ng/ml or less defines disease freedom for surgically staged men irradiated for prostate cancer. Urology 49:668-672, 1997.
49. Patel J, Worthen R, Abadir R, et al: Late results of combined iodine-125 and external beam radiotherapy in carcinoma of prostate. Urology 36:27-30, 1990.
50. Carey PO, Lippert MC, Constable WC, et al: Combined gold seed implantation and external radiotherapy for stage B2 or C prostate cancer. J Urol 139:989-994, 1988.
51. Lannon SG, El-Araby AA, Joseph PK, et al: Long-term results of combined interstitial gold seed implantation plus external beam irradiation on localized carcinoma of the prostate. Br J Urol 72:782-791, 1993.
52. Lerner SP, Seale-Hawkins C, Carlton CE, et al: The risk of dying of prostate cancer in patients with clinically localized prostate cancer. J Urol 146:1040-1045, 1991.
53. Eastham JA, Kattan MW, Groshen S, et al: Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer. J Clin Oncol 15:3214-3222, 1997.
54. Gomella LG, Steinberg SM, Ellison MF, et al: Analysis of iodine-125 interstitial therapy in the treatment of localized carcinoma of the prostate. J Surg Oncol 46:235-240, 1991.
55. Khan K, Thompson W, Bush S, et al: Transperineal percutaneous iridium-192 interstitial template implant of the prostate: Results and complications in 321 patients. Int J Radiat Oncol Biol Phys 22:935-939, 1992.
56. Syed AM, Puthawala A, Austin P, et al: Temporary iridium-192 implant in the management of carcinoma of the prostate. Cancer 69:2515-2524, 1992.
57. Stromberg JS, Martinez AA, Bensen R, et al: Improved local control and survival for surgically staged patients with locally advanced prostate cancer treated with up-front low-dose rate iridium-192 prostate implantation and external beam irradiation. Int J Radiat Oncol Biol Phys 28:67-75, 1994.
58. Donnelly BJ, Pedersen JE, Porter AT, et al: Iridium-192 brachytherapy in the treatment of cancer of the prostate. Urol Clin North Am 18:481-483, 1991.
59. Blasko JC, Ragde H, Luse RW, et al: Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin North Am 23:633-650, 1996.
60. Dattoli M, Wallner K, Sorace R, et al: Pd 103 brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys 35:875-879, 1996.
61. Kaye KW, Olson DJ, Payne JT: Detailed preliminary analysis of iodine 125 implantation for localized prostate cancer using percutaneous approach. J Urol 153:1020-1025, 1995.
62. Zeitlin SI, Sherman J, Raboy A, et al: High-dose combination radiotherapy for the treatment of localized prostate cancer. J Urol 160:91-96, 1998.
63. Iversen P, Bak M, Juul N, et al: Ultrasonically guided iodine-125 seed implantation with external radiation in management of localized prostatic carcinoma. Urology 34:181-186, 1989.
64. Waterman FM, Yue N, Corn BW, et al: Edema associated with 1-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: An analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys 41:1069-1077, 1998.
65. Robertson PL, Narayana V, McShan DL, et al: Source placement error for permanent implant of the prostate. Med Phys 24:251-257, 1997.
66. Prete JJ, Prestidge BR, Bice WS, et al: Comparison of MRI-and CT-based postimplant dosimetric analysis of transperineal interstitial permanent prostate brachytherapy. Radiat Oncol Invest 6:90-96, 1998.
67. Stromberg JS, Martinez AA, Horwitz EM, et al: Conformal high-dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: Superior prostate-specific antigen response compared with external beam treatment. Cancer J Sci Am 3:346-352, 1997.
68. Deger S, Dinges S, Roigas J, et al: High-dose rate iridium-192 afterloading therapy in combination with external beam irradiation for localized prostate cancer. Tech Urol 3:190-194, 1997.
69. Paul R, Hofmann R, Schwarzer JU, et al: Iridium-192 high-dose-rate brachytherapy - a useful alternative therapy for localized prostate cancer? World J Urol 15:252-256, 1997.
70. Mate TP, Gottesman JE, Hatton J, et al: High dose-rate afterloading iridium-192 prostate brachytherapy: Feasibility report. Int J Radiat Oncol Biol Phys 41:525-533, 1998.
71. Kovacs G, Galalae R. High dose-rate brachytherapy of prostate cancer: German experience. Proc 9th Int Brachyther Conf, pp 84-85, 1997.
72. Borghede G, Hedelin H, Holmang S, et al: Combined treatment with temporary short-term high-dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma. Radiother Oncol 44:237-244, 1997.
73. Borghede G, Hedelin H, Holmang S, et al: Irradiation of localized prostatic carcinoma with a combination of high-dose rate iridium-192 brachytherapy and external beam radiotherapy with three target definitions and dose levels inside the prostate gland. Radiother Oncol 44:245-250, 1997.
74. Prestidge BR, Butler B, Shaw D, et al: Ultrasound guided placement of transperineal prostatic afterloading catheters. Int J Radiat Oncol Biol Phys 28:263-266, 1993.
75. Martinez AM, Gonzalez J, Stromberg J, et al: Conformal prostate brachytherapy: Initial experience of a phase I/II dose-escalating trial. Int J Radiat Oncol Biol Phys 33:1019-1027, 1995.
76. Kini VR, Edmundson GK, Vicini FA, et al: Use of three-dimensional radiation therapy planning tools and intraoperative ultrasound to evaluate high-dose rate prostate brachytherapy inplants. Int J Radiat Oncol Biol Phys, 1999 (in press).
77. Oefelein MG, Smith ND, Grayhack JT, et al: Long-term results of radical retropubic prostatectomy in men with high-grade carcinoma of the prostate. J Urol 158:1460-1465, 1997.